{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:04:15Z","timestamp":1792263855210,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Developing a safe and effective vaccine remains a global priority for ending the human immunodeficiency virus (HIV) pandemic. All HIV vaccine trials with protein, DNA, non-replication vector or their combinations failed in the past. We constructed the HIV-1 CN54 <jats:italic>env<\/jats:italic>, <jats:italic>gag<\/jats:italic>, and <jats:italic>pol<\/jats:italic> genes into both DNA and replicating vaccinia virus Tiantan vectors. In phase Ia, 12 healthy adults were given high (<jats:italic>n<\/jats:italic>\u2009=\u20096) or low (<jats:italic>n<\/jats:italic>\u2009=\u20096) doses of recombinant vaccinia virus Tiantan vaccine (rTV), to test its safety dose. In phase Ib, 36 healthy adults were assigned to the DNA (<jats:italic>n<\/jats:italic>\u2009=\u20096), DNA-L\/rTV (<jats:italic>n<\/jats:italic>\u2009=\u200912), DNA-H\/rTV (<jats:italic>n<\/jats:italic>\u2009=\u200912), and placebo (<jats:italic>n<\/jats:italic>\u2009=\u20096) groups. The DNA vaccine was injected intramuscularly at weeks 0, 4, and 8 and rTV with a bifurcated needle at week 12. All vaccines tested were safe and well-tolerated; most of the adverse events (AEs) were mild to moderate. The most commonly observed AEs were redness and papule at rTV vaccination sites and axillary enlarged lymph nodes at the same rTV vaccination arm. Smaller cutaneous lesions and shorter healing time were observed in smallpox vaccine experienced subjects. The DNA prime-rTV boost regimen induced anti-gp120 IgG and polyfunctional CD4<jats:sup>+<\/jats:sup> T cells. No significant differences of anti-HIV IgG and T cell responses were found between the two prime-boost groups with high and low DNA doses. Moreover, smallpox vaccine na\u00efve subjects elicited higher T cell responses and anti-gp120 antibodies. The result of this trial supports further development of HIV vaccine with DNA and replicating vaccinia vector for advanced clinical trials.<\/jats:p>","DOI":"10.1038\/s41392-025-02259-y","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T23:03:14Z","timestamp":1751410994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety and immunogenicity of an HIV vaccine trial with DNA prime and replicating vaccinia boost"],"prefix":"10.1038","volume":"10","author":[{"given":"Ying","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Qi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Chun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Ling","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4246-8889","authenticated-orcid":false,"given":"Wei-Jin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Sheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ming","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"2259_CR1","unstructured":"UNAIDS. Global HIV & AIDS statistics\u20142023 Fact sheet, https:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"key":"2259_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1001\/jama.2017.13505","volume":"318","author":"AS Fauci","year":"2017","unstructured":"Fauci, A. S. An HIV vaccine is essential for ending the HIV\/AIDS pandemic. JAMA 318, 2 (2017).","journal-title":"JAMA"},{"key":"2259_CR3","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.idc.2024.04.004","volume":"38","author":"DS Graciaa","year":"2024","unstructured":"Graciaa, D. S., Walsh, S. R. & Rouphael, N. Human immunodeficiency virus vaccine: promise and challenges. Infect. Dis. Clin. North. Am. 38, 475\u2013485 (2024).","journal-title":"Infect. Dis. Clin. North. Am."},{"key":"2259_CR4","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","volume":"361","author":"S Rerks-Ngarm","year":"2009","unstructured":"Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209\u20132220 (2009).","journal-title":"N. Engl. J. Med."},{"key":"2259_CR5","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1097\/COH.0000000000000322","volume":"11","author":"ND Russell","year":"2016","unstructured":"Russell, N. D. & Marovich, M. A. Pox-Protein Public Private Partnership program and upcoming HIV vaccine efficacy trials. Curr. Opin. HIV AIDS 11, 614\u2013619 (2016).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"2259_CR6","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2031499","volume":"384","author":"GE Gray","year":"2021","unstructured":"Gray, G. E. et al. Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120-MF59 in adults. N. Engl. J. Med. 384, 1089\u20131100 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2259_CR7","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/infdis\/jiy212","volume":"218","author":"LR Baden","year":"2018","unstructured":"Baden, L. R. et al. First-in-human randomized, controlled trial of mosaic HIV-1 immunogens delivered via a modified vaccinia Ankara vector. J. Infect. Dis. 218, 633\u2013644 (2018).","journal-title":"J. Infect. Dis."},{"key":"2259_CR8","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/S0140-6736(18)31364-3","volume":"392","author":"DH Barouch","year":"2018","unstructured":"Barouch, D. H. et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet 392, 232\u2013243 (2018).","journal-title":"Lancet"},{"key":"2259_CR9","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1016\/S2352-3018(23)00264-3","volume":"11","author":"JP Nkolola","year":"2024","unstructured":"Nkolola, J. P. & Barouch, D. H. Prophylactic HIV-1 vaccine trials: past, present, and future. Lancet HIV 11, e117\u2013e124 (2024).","journal-title":"Lancet HIV"},{"key":"2259_CR10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/COH.0b013e328363d389","volume":"8","author":"CL Parks","year":"2013","unstructured":"Parks, C. L., Picker, L. J. & King, C. R. Development of replication-competent viral vectors for HIV vaccine delivery. Curr. Opin. HIV AIDS 8, 402\u2013411 (2013).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"2259_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/JCI140794","volume":"131","author":"K Matsuda","year":"2021","unstructured":"Matsuda, K. et al. A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity. J. Clin. Investig. 131, 1 (2021).","journal-title":"J. Clin. Investig."},{"key":"2259_CR12","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1126\/sciimmunol.aau2710","volume":"4","author":"K Matsuda","year":"2019","unstructured":"Matsuda, K. et al. Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine. Sci. Immunol. 4, 2710 (2019).","journal-title":"Sci. Immunol"},{"key":"2259_CR13","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1586\/14760584.3.4.S105","volume":"3","author":"NV Malkevitch","year":"2004","unstructured":"Malkevitch, N. V. & Robert-Guroff, M. A call for replicating vector prime-protein boost strategies in HIV vaccine design. Expert Rev. Vaccines 3, S105\u2013S117 (2004).","journal-title":"Expert Rev. Vaccines"},{"key":"2259_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/infdis\/jiw500","volume":"215","author":"J Nyombayire","year":"2017","unstructured":"Nyombayire, J. et al. First-in-human evaluation of the safety and immunogenicity of an intranasally administered replication-competent Sendai virus-vectored HIV type 1 gag vaccine: induction of potent T-cell or antibody responses in prime-boost regimens. J. Infect. Dis. 215, 95\u2013104 (2017).","journal-title":"J. Infect. Dis."},{"key":"2259_CR15","doi-asserted-by":"publisher","first-page":"870","DOI":"10.3390\/v16060870","volume":"16","author":"J Hsu","year":"2024","unstructured":"Hsu, J., Kim, S., & Anandasabapathy, N. Vaccinia virus: mechanisms supporting immune evasion and successful long-term protective immunity. Viruses 16, 870 (2024).","journal-title":"Viruses"},{"key":"2259_CR16","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3390\/v16040620","volume":"16","author":"S Mariotti","year":"2024","unstructured":"Mariotti, S. et al. Antibodies induced by smallpox vaccination after at least 45 years cross-react with and in vitro neutralize Mpox virus: a role for polyclonal B cell activation?. Viruses 16, 620 (2024).","journal-title":"Viruses"},{"key":"2259_CR17","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/QAD.0000000000000595","volume":"29","author":"Q Liu","year":"2015","unstructured":"Liu, Q. et al. HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection. AIDS 29, 649\u2013658 (2015).","journal-title":"AIDS"},{"key":"2259_CR18","first-page":"1","volume":"50","author":"LD Rotz","year":"2001","unstructured":"Rotz, L. D., Dotson, D. A., Damon, I. K. & Becher, J. A. Advisory Committee on Immunization Practices. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm. Rep. 50, 1\u201325 (2001).","journal-title":"MMWR Recomm. Rep."},{"key":"2259_CR19","first-page":"1","volume":"52","author":"J Cono","year":"2003","unstructured":"Cono, J., Casey, C. G. & Bell, D. M. Centers for Disease Control and Prevention. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm. Rep. 52, 1\u201328 (2003).","journal-title":"MMWR Recomm. Rep."},{"key":"2259_CR20","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1056\/NEJMoa020534","volume":"346","author":"SE Frey","year":"2002","unstructured":"Frey, S. E. et al. Clinical responses to undiluted and diluted smallpox vaccine. N. Engl. J. Med. 346, 1265\u20131274 (2002).","journal-title":"N. Engl. J. Med."},{"key":"2259_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jacc.2004.05.004","volume":"44","author":"RE Eckart","year":"2004","unstructured":"Eckart, R. E. et al. Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. J. Am. Coll. Cardiol. 44, 201\u2013205 (2004).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2259_CR22","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1310566","volume":"369","author":"SM Hammer","year":"2013","unstructured":"Hammer, S. M. et al. Efficacy trial of a DNA\/rAd5 HIV-1 preventive vaccine. N. Engl. J. Med. 369, 2083\u20132092 (2013).","journal-title":"N. Engl. J. Med."},{"key":"2259_CR23","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nbt.3187","volume":"33","author":"L Lin","year":"2015","unstructured":"Lin, L. et al. COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat. Biotechnol. 33, 610\u2013616 (2015).","journal-title":"Nat. Biotechnol."},{"key":"2259_CR24","doi-asserted-by":"publisher","first-page":"e1003479","DOI":"10.1371\/journal.ppat.1003479","volume":"9","author":"DJ Perkins","year":"2013","unstructured":"Perkins, D. J. et al. Reprogramming of murine macrophages through TLR2 confers viral resistance via TRAF3-mediated, enhanced interferon production. PLoS Pathog. 9, e1003479 (2013).","journal-title":"PLoS Pathog."},{"key":"2259_CR25","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1128\/jvi.62.5.1530-1534.1988","volume":"62","author":"JF Rooney","year":"1988","unstructured":"Rooney, J. F., Wohlenberg, C., Cremer, K. J., Moss, B. & Notkins, A. L. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination. J. Virol. 62, 1530\u20131534 (1988).","journal-title":"J. Virol."},{"key":"2259_CR26","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2307\/1592516","volume":"44","author":"DE Swayne","year":"2000","unstructured":"Swayne, D. E., Beck, J. R. & Kinney, N. Failure of a recombinant fowl poxvirus vaccine containing an avian influenza hemagglutinin gene to provide consistent protection against influenza in chickens preimmunized with a fowl pox vaccine. Avian Dis. 44, 132\u2013137 (2000).","journal-title":"Avian Dis."},{"key":"2259_CR27","doi-asserted-by":"publisher","first-page":"7262","DOI":"10.4049\/jimmunol.1000751","volume":"185","author":"S Kannanganat","year":"2010","unstructured":"Kannanganat, S. et al. Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA\/MVA vaccine. J. Immunol. 185, 7262\u20137273 (2010).","journal-title":"J. Immunol."},{"key":"2259_CR28","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/j.vaccine.2013.01.038","volume":"31","author":"JN Brewoo","year":"2013","unstructured":"Brewoo, J. N. et al. Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice. Vaccine 31, 1848\u20131855 (2013).","journal-title":"Vaccine"},{"key":"2259_CR29","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/S1473-3099(14)70963-6","volume":"14","author":"JH Kreijtz","year":"2014","unstructured":"Kreijtz, J. H. et al. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1\/2a clinical trial. Lancet Infect. Dis. 14, 1196\u20131207 (2014).","journal-title":"Lancet Infect. Dis."},{"key":"2259_CR30","doi-asserted-by":"publisher","first-page":"4468","DOI":"10.1016\/j.vaccine.2009.05.018","volume":"27","author":"L Gudmundsdotter","year":"2009","unstructured":"Gudmundsdotter, L. et al. Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine 27, 4468\u20134474 (2009).","journal-title":"Vaccine"},{"key":"2259_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1084\/jem.20071331","volume":"205","author":"A Harari","year":"2008","unstructured":"Harari, A. et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J. Exp. Med 205, 63\u201377 (2008).","journal-title":"J. Exp. Med"},{"key":"2259_CR32","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1001\/jama.289.24.3290","volume":"289","author":"TR Talbot","year":"2003","unstructured":"Talbot, T. R. Focal and generalized folliculitis following smallpox vaccination among vaccinia-naive recipients. JAMA 289, 3290\u20133294 (2003).","journal-title":"JAMA"},{"key":"2259_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6404a1","volume":"64","author":"BW Petersen","year":"2015","unstructured":"Petersen, B. W. et al. Clinical guidance for smallpox vaccine use in a postevent vaccination program. MMWR Recomm. Rep. 64, 1\u201326 (2015).","journal-title":"MMWR Recomm. Rep."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02259-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02259-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02259-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T23:03:15Z","timestamp":1751410995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02259-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2259"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02259-y","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"30 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"208"}}